Our data support a role for miR-130b in promoting the aggressiveness of LMS, in part by repressing TSC1, a tumor suppressor that controls anabolic cell growth and differentiation through inhibition of mammalian target of rapamycin (mTOR) [52]. The gene discussed is TSC1; the disease is neoplasm.